UOC
XENE icon

UBS O'Connor’s Xenon Pharmaceuticals XENE Stock Holding History

UBS O'Connor’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-7,987
Closed -$344K – 643
2024
Q1 		$344K Sell
7,987
-6,689
-46% -$308K 0.01% 362
2023
Q4 		$676K Sell
14,676
-34,000
-70% -$1.2M 0.02% 319
2023
Q3 		$1.66M Buy
48,676
+10,000
+26% +$374K 0.03% 266
2023
Q2 		$1.49M Sell
38,676
-24,715
-39% -$982K 0.03% 340
2023
Q1 		$2.27M Buy
+63,391
New +$2.34M 0.05% 295
2022
Q4 		– Sell
-54,208
Closed -$1.96M – 340
2022
Q3 		$1.96M Sell
54,208
-42,000
-44% -$1.51M 0.02% 629
2022
Q2 		$2.93M Buy
+96,208
New +$2.91M 0.03% 473

Other funds holding XENE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

UBS O'Connor's XENE Position: Q2 2024 in Review

UBS O'Connor sold out of Xenon Pharmaceuticals (XENE) in Q2 2024, closing a stake of 7,987 shares — an estimated $344K sold.

UBS O'Connor first reported a position in XENE in Q2 2022 and held it in 7 quarters. The position peaked at $2.93M in Q2 2022. 213 funds tracked by Wall St. Rank hold XENE as of Q2 2024.

  • UBS O'Connor reported no remaining Xenon Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • UBS O'Connor sold 7,987 Xenon Pharmaceuticals shares in Q2 2024, an estimated $344K.
  • UBS O'Connor first reported a position in Xenon Pharmaceuticals in Q2 2022 and held it in 7 quarters.
  • UBS O'Connor's Xenon Pharmaceuticals position peaked at $2.93M in Q2 2022.
  • 213 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q2 2024.

Based on UBS O'Connor's 13F filing for Q2 2024, filed 14 Aug 2024.